Applicant: Jeffrey S. Ross Attorney's Docket No.: M2051-700410 / MPI03-005P1R

Serial No.: 10/736,112

Filed: December 15, 2003

Page : 2 of 13

Amendment to the Specification:

Please amend the paragraph beginning at page 17, line 4 as follows:

As used herein, "PSMA" or "prostate-specific membrane antigen" protein refers to mammalian PSMA, preferably human PSMA protein and dimers thereof. Human PSMA includes the two protein products, PSMA and PSM', encoded by the two alternatively spliced mRNA variants (containing about 2,653 and 2,387 nucleotides, respectively) of the PSMA cDNA disclosed in Israeli *et al.* (1993) *Cancer Res.* 53:227-230; Su *et al.* (1995) *Cancer Res.* 55:1441-1443; US 5,538,866, US 5,935,818, and WO 97/35616, the contents of which are hereby incorporated by reference. The long transcript of PSMA encodes a protein product of about 100-120 kDa molecular weight characterized as a type II transmembrane receptor having sequence homology with the transferrin receptor and having NAALADase activity (Carter et al. (1996) *Proc. Natl. Acad. Sci.* USA 93:749-753). Accordingly, the term "human PSMA" refers to at least two protein products, human PSMA and PSM', which have or are homologous to (e.g., at least about 85%, 90%, 95% identical to) an amino acid sequence: as shown in Israeli *et al.* (1993) *Cancer Res.* 53:227-230; Su *et al.* (1995) *Cancer Res.* 55:1441-1443; US 5,538,866, US 5,935,818, and WO 97/35616

MetTrpAsnLeuLeuHisGluThrAspSerAlaValAlaThrAlaArgArgProArgTrpLeuCysAlaGly AlaLeuValLeuAlaGlyGlyPhePheLeuLeuGlyPheLeuPheGlyTrpPheIleLysSerSerAsnGluAlaThrA snIleThrProLysHisAsnMetLysAlaPheLeuAspGluLeuLysAlaGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAlaGlyThrGluGlnAsnPheGlnLeuAlaLysGlnIleGlnSerGlnTrpLysGluPheGlyLeuAspSerValGluLeuAlaHisTyrAspValLeuLeuSerTyrProAsnLysThrHisProAsnTyrIleSerIleIleAsnGluAspGlyAsnGluIlePheAsnThrSerLeuPheGluProProProProGlyTyrGluAsnValSerAspIleValProProPheSerAlaPheSerProGlnGlyMetProGluGlyAspLeuValTyrValAsnTyrAlaArgThrGluAspPhePheLysLeuGluArgAspMetLysIleAsnCysSerGlyLysIleValIleAlaArgTyrGlyLysValPheArgGlyAsnLysValLysAsnAlaGlnLeuAlaGlyAlaLysGlyValIleLeuTyrSerAspProAlaAspTyrPheAlaProGlyValLysSerTyrProAspGlyTrpAsnLeuProGlyGlyGlyValGlnArgGlyAsnIleLeuAsnLeuAsnGlyAlaGlyAspProLeuThrProGlyTyrProAlaAsnGluTyrAlaTyrArgArgGlyIleAlaGluAlaValGlyLeuProSerIleProValHisProIleGlyTyrTyrAspAlaGlnLysLeuLeuGluLysMetGlyGlySerAlaProProAspSerSerTrpArgGlySerLeuLysValProTyrAsnValGlyProGlyPheThrGlyAsnPheSerThrGlnLysValL

Applicant: Jeffrey S. Ross Attorney's Docket No.: M2051-700410 / MPI03-005P1R

Serial No.: 10/736,112 : December 15, 2003

Filed

: 3 of 13 Page

ysMetHisIleHisSerThrAsnGluValThrArgIleTyrAsnValIleGlyThrLeuArgGlyAlaValGluProAspA rgTyrValIleLeuGlyGlyHisArgAspSerTrpValPheGlyGlyIleAspProGlnSerGlyAlaAlaValValHisG lulleValArgSerPheGlyThrLeuLysLysGluGlyTrpArgProArgArgThrIleLeuPheAlaSerTrpAspAlaGluGluPheGlyLeuLeuGlySerThrGluTrpAlaGluGluAsnSerArgLeuLeuGlnGluArgGlyValAlaTyr Ile AsnAla Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asp Cys Thr Pro Leu Weight Cys Thr PronLeuThrLysGluLeuLysSerProAspGluGlyPheGluGlyLysSerLeuTyrGluSerTrpThrLysLysSerPro SerProGluPheSerGlyMetProArgIleSerLysLeuGlySerGlyAsnAspPheGluValPhePheGlnArgLeuG lylleAlaSerGlyArgAlaArgTyrThrLysAsnTrpGluThrAsnLysPheSerGlyTyrProLeuTyrHisSerVal TyrGluThrTyrGluLeuValGluLysPheTyrAspProMetPheLysTyrHisLeuThrValAlaGlnValArgGly GlyMetValPheGluLeuAlaAsnSerIleValLeuProPheAspCysArgAspTyrAlaValValLeuArgLysTyrAlaAspLysIleTyrSerIleSerMetLysHisProGlnGluMetLysThrTyrSerValSerPheAspSerLeuPheSer AlaValLysAsnPheThrGluIleAlaSerLysPheSerGluArgLeuGlnAspPheAspLysSerAsnProIleValLe $\underline{uArgMetMetAsnAspGlnLeuMetPheLeuGluArgAlaPheIleAspProLeuGlyLeuProAspArgProPheT}$ yrArgHisValIleTyrAlaProSerSerHisAsnLysTyrAlaGlyGluSerPheProGlyIleTyrAspAlaLeuPheA spIleGluSerLysValAspProSerLysAlaTrpGlyGluValLysArgGlnIleTyrValAlaAlaPheThrValGlnA laAlaAlaGluThrLeuSerGluValAla (SEQ ID NO:1) or

MetLysAlaPheLeuAspGluLeuLysAlaGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluLeuLysAlaPheLeuAspGluLeuLysAlaGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluLeuLysAlaPheLeuAspGluLeuLysAlaGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluAspAlaGluAsnIleLysLysPheLeuTyrAsnPheThrGlnIleProHisLeuAspGluAspAlaGluAAlaGlyThrGluGlnAsnPheGlnLeuAlaLysGlnIleGlnSerGlnTrpLysGluPheGlyLeuAspSerValGluL euAlaHisTyrAspValLeuLeuSerTyrProAsnLysThrHisProAsnTyrIleSerIleIleAsnGluAspGlyAsnG lulle Phe Asn Thr Ser Leu Phe Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro Phe Ser Ala Phenomena (No. 1997). The properties of the propeSerProGlnGlyMetProGluGlyAspLeuValTyrValAsnTyrAlaArgThrGluAspPhePheLysLeuGluAr gAspMetLysIleAsnCysSerGlyLysIleValIleAlaArgTyrGlyLysValPheArgGlyAsnLysValLysValLysValLysAsnLysValLysValLysAsnLysValLysAlaGlnLeuAlaGlyAlaLysGlyValIleLeuTyrSerAspProAlaAspTyrPheAlaProGlyValLysSerTyrPr oAspGlyTrpAsnLeuProGlyGlyGlyValGlnArgGlyAsnIleLeuAsnLeuAsnGlyAlaGlyAspProLeuTunderforder (Annal Manager) and the support of the property ofhrProGlyTyrProAlaAsnGluTyrAlaTyrArgArgGlylleAlaGluAlaValGlyLeuProSerIleProValHisPr olleGlyTyrTyrAspAlaGlnLysLeuLeuGluLysMetGlyGlySerAlaProProAspSerSerTrpArgGlySerL euLysValProTyrAsnValGlyProGlyPheThrGlyAsnPheSerThrGlnLysValLysMetHisIleHisSerThr AsnGluValThrArgIleTyrAsnValIleGlyThrLeuArgGlyAlaValGluProAspArgTyrValIleLeuGlyGl yHisArgAspSerTrpValPheGlyGlyIleAspProGlnSerGlyAlaAlaValValHisGluIleValArgSerPheGl

Applicant: Jeffrey S. Ross Attorney's Docket No.: M2051-700410 / MPI03-005P1R

Serial No.: 10/736,112 Filed : December 15, 2003

: 4 of 13 Page

y Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr I le Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Phe Ala Ser Trp Asp Ala Glu Gly Phe Gly Leu Leu Phe Ala Ser Trp Asp Ala Glu Gly Phe Gly Leu Leu Phe Ala Ser Trp Asp Ala Gly Phe Gly Leu Leu Phe Ala Ser Trp Asp Ala Gly Phe Gly Phe Ala Ser Trp Asp Ala Gly Phe Gly Phe Ala Ser Trp Asp Ala Gly Phe Gly Phe Ala Ser Trp Asp Ala Gly Phe Ala Ser Trp Asp Ala Gly Phe Gly Phe Ala Ser Trp Asp Ala Gly Phe Ala Ser TGlySerThrGluTrpAlaGluGluAsnSerArgLeuLeuGlnGluArgGlyValAlaTyrIleAsnAlaAspSerSerIl eGluGlyAsnTyrThrLeuArgValAspCysThrProLeuMetTyrSerLeuValHisAsnLeuThrLysGluLeuLysSerProAspGluGlyPheGluGlyLysSerLeuTyrGluSerTrpThrLysLysSerProSerProGluPheSerGly MetProArgIleSerLysLeuGlySerGlyAsnAspPheGluValPhePheGlnArgLeuGlyIleAlaSerGlyArgAl ValGluLysPheTyrAspProMetPheLysTyrHisLeuThrValAlaGlnValArgGlyGlyMetValPheGluLeu AlaAsnSerIleValLeuProPheAspCysArgAspTyrAlaValValLeuArgLysTyrAlaAspLysIleTyrSerIle Ser Met Lys His Pro Gln Glu Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys His Pro Gln Glu Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Thr Grant Global Met Lys Thr Tyr Ser Val Ser Phe Thr Tyr SelulleAlaSerLysPheSerGluArgLeuGlnAspPheAspLysSerAsnProIleValLeuArgMetMetAsnAspGl nLeuMetPheLeuGluArgAlaPheIleAspProLeuGlyLeuProAspArgProPheTyrArgHisValIleTyrAla ProSerSerHisAsnLysTyrAlaGlyGluSerPheProGlyIleTyrAspAlaLeuPheAspIleGluSerLysValAsp ProSerLysAlaTrpGlyGluValLysArgGlnIleTyrValAlaAlaAlaPheThrValGlnAlaAlaAlaGluThrLeuSerGluValAla (SEQ ID NO:2); or which is encoded by (a) a naturally occurring human PSMA nucleic acid sequence (e.g., Israeli et al. (1993) Cancer Res. 53:227-230 or US 5.538.866); (b) a nucleic acid sequence degenerate to a naturally occurring human PSMA sequence; (c) a nucleic acid sequence homologous to (e.g., at least about 85%, 90%, 95% identical to) the naturally occurring human PSMA nucleic acid sequence; or (d) a nucleic acid sequence that hybridizes to one of the foregoing nucleic acid sequences under stringent conditions, e.g., highly stringent conditions.